Phathom Pharmaceuticals reports Q3 adjusted EPS (15c), consensus (41c)

Reports Q3 revenue $49.5M, consensus $46.99M. “Our performance this quarter reinforces our belief in the strength of our GI-focused call strategy and reflects disciplined execution across the business,” said Steve Basta, President and Chief Executive Officer of Phathom. “Momentum for VOQUEZNA tablets continues to build as we deepen engagement with gastroenterologists. In the third quarter we grew revenues, reduced expenses, and reduced cash usage in line with our previously communicated plan. With strong commercial performance this quarter, continued expense discipline, and an experienced leadership team in place, we are advancing toward our goal of becoming a leader in GI.”